Diabetic mice models treated with liraglutide were shown to have improved glucose metabolism and insulin resistance, reduced PASI, and decreased expression of IL-23, IL-17, IL-22, and TNF- in skin tissue
Like liraglutide, semaglutide incorporates an Aib substitution at the 8th position in place of Ala, which confers resistance to enzymatic degradation by DPP-4
The conversion guidance that exists for transitioning between other GLP-1 agonists can provide some framework for thinking about dosing during transitions, though no specific tirzepatide-to-retatrutide conversion protocol has been established in clinical literature
Examples include Ozempic, Wegovy, Mounjaro, and Zepbound
The announcement received modest media attention, buried beneath the oversaturated coverage of GLP-1s in lifestyle media